

Conference Programme

DAY 1 – Wednesday 31st Aug 2022 – WELCOME FUNCTION	
Crowne Plaza Queenstown	
18.30 – 18.35	Welcome Hesh Al-Sallami <i>President/Chair of ASCEPT NZ</i>
18.35 – 19.30	Registration opens. Drinks, nibbles, and networking function


DAY 2 – Thursday 1st Sept 2022 – ANNUAL SCIENTIFIC MEETING	
08.30 – 08.55	Registration opens. Tea and coffee available
Welcome – Hesh Al-Sallami	
Oral Communications 1 – Chair: Prof Michelle Glass	
09.00 – 09.15	(A1) Synthesis of polymeric iNOS antagonist prodrug for targeted inhibition of inflammation induced angiogenesis Houman Alimoradi Department of Anatomy, Brain Health Research Centre, University of Otago Brain Research New Zealand
09.15 – 09.30	(A2) From a phase III clinical vascular disrupting agent to a target based immunomodulator, the rise of xanthenones Jack Flanagan Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, University of Auckland
09.30 – 09.45	(A3) Using Bayesian software to inform initial busulfan dose in adults receiving haematopoietic stem cell transplantation Marie-Claire Morahan Department of Clinical Pharmacology, Canterbury District Health Board, Christchurch
09.45 – 10.00	(A4) An Old Drug with New Tricks; Examining the Action of Metformin in ALK+ Lung Cancer Abigail Bland Department of Pharmacology and Toxicology, University of Otago

10.00 – 10.15	(A5) Omeprazole treatment failure in gastro-oesophageal reflux disease and genetic variation at the CYP2C locus Ping Siu Kee Department of Pathology and Biomedical Science, University of Otago, Christchurch
10.15 – 10.30	(A6) The dual benefits of 5HT₃ receptor antagonists in cancer therapy Anita Barzegar-Fallah Department of Pharmacology and Toxicology, University of Otago
10.30 – 11.00	Morning tea
Student Presentations 1 – Chair: Dr Katie Burns	
11.15 – 11.30	(A7) Examining the Effect of the Novel Cardioprotective Agent oCom-21 on the NLRP3 Inflammasome in an Ex Vivo Rat Model of Cardiac Ischaemic Reperfusion Injury Alisha Dabb Department of Pharmacology and Toxicology, University of Otago
11.30 – 11:45	(A8) Delineating the interactions between the cannabinoid CB₂ receptor and its regulatory effectors; β-arrestin 2 and G protein-coupled receptor kinases Monica Patel Department of Pharmacology and Toxicology, University of Otago
11.45 – 12.00	(A9) Investigating G protein vs β-arrestin bias of late-generation synthetic cannabinoids at the CB1 receptor Beth Ehrlich Department of Pharmacology and Toxicology, University of Otago
12.00 – 12.15	(A10) The predictive performance of an allopurinol adherence monitoring tool for clinical trials Natalia Smith Diaz (presented by Dan Wright) School of Pharmacy, University of Otago
12.15 – 12.30	(A11) Novel thermoresponsive hydrogels (NTH) to prevent reactive gliosis after stroke Mozammel Haque Bhuiyan Center for Bioengineering and Nanomedicine, Faculty of Dentistry, University of Otago Department of Anatomy, Brain Health Research Centre and Brain Research New Zealand, University of Otago
12.30 – 12.45	(A12) Differential interaction of β-arrestin for two CGRP-responsive receptors Tyla Alexander Department of Pharmacology and Toxicology, University of Otago
12.45 – 13.45	Lunch

Symposium – Adverse Drug Reactions, a testing issue – Chair: Assoc Prof Matt Doogue	
13.45 – 14.15	(A13) Genomic analysis of angiotensin converting enzyme inhibitor - induced angioedema. <i>Prof Martin Kennedy, University of Otago, Christchurch</i>
14.15 – 14.45	(A14) Testing for dihydropyrimidine dehydrogenase deficiency in New Zealand to improve the safe use of 5-fluorouracil and capecitabine in cancer patients <i>Assoc/Prof Nuala Helsby, University of Auckland</i>
14.45 – 15.15	(A15) Cannabinoids as Opioid Sparing Agents <i>Associate Professor Bridin Murnion</i>
15.15 – 15.30	Panel Discussion – Studying ADRs in New Zealand
15.30 – 16.00	Afternoon tea
Student Presentations 2 – Chair: Dr Jacqui Hannam	
16.00 – 16.15	(A16) The effect of mandatory prescription indications for antibacterials Lorna Pairman Department of Medicine, University of Otago, Christchurch
16.15 – 16.30	(A17) Evaluation of the appropriateness of the prior for incorporation into therapeutic drug monitoring software – an application to Infliximab Alexandra McLennan Otago Pharmacometrics Group, University of Otago
16.30 – 16.45	(A18) Exploring Go / No-Go with Oral Docetaxel plus Encequidar David Wang Otago Pharmacometrics Group, University of Otago
16.45 – 17.00	(A19) Co-expression of CGRP, amylin and the CTR in the dorsal root ganglia and spinal cord of mice, rats and humans Rees, T.A. School of Biological Sciences, University of Auckland, Auckland
17.00 – 17.15	(A20) Cellular uptake of clozapine and its major metabolites Philippa Campbell Dept of Pharmacology and Clinical Pharmacology, University of Auckland
17.15 – 17.20	Comfort Break
17.20 – 18.10	ASCEPT AGM
19.00	Conference dinner Blue Kanu, 16 Church Street, Queenstown

CONFERENCE DINNER

Blue Kanu (<https://www.bluekanu.co.nz/>) is a short walk from the Crowne Plaza (~400 m or 5 min).



DAY 3 – Friday 2nd Sept 2022 – ANNUAL SCIENTIFIC MEETING

Invited Speaker – Chair: Assoc Prof Ivan Sammut

09.00 – 09.30

(A21)

A new hope: Calcitonin gene-related peptide blocking drugs in migraine

Prof Debbie Hay

Department of Pharmacology and Toxicology, University of Otago

Student Presentations 3 – Chair: Assoc Prof Nuala Helsby

09.30 – 09.45

(A22)

Prophylactic organic carbon monoxide donors protect hypertrophic hearts against ischaemia-reperfusion injury

SH Thwaite

Dept of Pharmacology & Toxicology, University of Otago

09.45 – 10.00

(A23)

Carbon Monoxide Release by oCOM-21 Enhances Ca²⁺ Sensitivity of the Cardiac Myofilament

Fergus Payne

Department of Pharmacology and Toxicology, University of Otago

10.00 – 10.15

(A24)

Antibiotic pharmacodynamics: effect of exposure on renal function

Conor O'Hanlon

Department of Pharmacology and Clinical Pharmacology¹, University of Auckland

10.15 – 10.30	(A25) Reactive Oxygen Species associated with CYP-catalysed Cycling of Clozapine to Clozapine-N-oxide Ellen Kingston Department of Pharmacology and Clinical Pharmacology, University of Auckland
10.30 – 11.00	Morning tea
Student Presentations 4 – Chair: Assoc Prof Matt Doogue	
11.00 – 11.15	(A26) Sevoflurane pharmacokinetics and pharmacodynamics in adults during general anaesthesia James Morse Department of Pharmacology and Clinical Pharmacology, University of Auckland
11.15 – 11.30	(A27) Combination of ALK and SHP2 inhibitors produce synergistic suppression of ALK-positive lung cancer cell growth Madeleine Berry Department of Pharmacology and Toxicology, University of Otago
11.30 – 11.45	(A28) Tumour cell suppression by Spiroleucettadine through dual regulation of cell cycle and apoptosis Ben Watts (presented by John Ashton) Department of Pharmacology and Toxicology, University of Otago
11.45 – 12.00	(A29) Positive allosteric modulation of the type 1 cannabinoid receptor potentiates endocannabinoid signalling and changes ERK1/2 phosphorylation kinetics. Hayley Green Department of Pharmacology and Toxicology, University of Otago
12.00 – 12.15	(A30) Optimal insulin initiation dose in children with type 1 diabetes mellitus Isabelle Lim (presented by Hesh Al-Sallami) Otago Pharmacometrics Group, University of Otago
12.15 – 13.10	Lunch
ASCEPT Guest Speaker – Chair: Assoc Prof Hesh Al-Sallami	
13.10 – 13.40	(A31) via Zoom Adverse Drug Reactions in Older Adults <i>Assoc Prof Danijela Gnjidic</i> School of Pharmacy, Faculty of Medicine and Health, University of Sydney
Oral Communications 2 – Chair: Assoc Prof Malcolm Tingle	

13.40 – 13.55	<p>(A32) Extracellular bimolecular fluorescence complementation assays for investigating receptor dimerization: a proof of concept with receptors for calcitonin gene-related peptide Michael Garelja Department of Pharmacology and Toxicology, University of Otago</p>
13.55 – 14.10	<p>(A33) Investigating the signalling of an atypical group of receptors – GPCR bigrams Gabriel Rawcliffe Department of Pharmacology and Toxicology, University of Otago</p>
14.10 – 14.25	<p>(A34) A survey of 6-thioguanine use by gastroenterology clinicians for inflammatory bowel disease Murray Barclay Department of Clinical Pharmacology, Christchurch Hospital, University of Otago</p>
14.25 – 14:55	<p>Conference Close and Prize Giving “In memory of Prof Fred Fastier”</p>